| Budget Amount *help |
¥45,000,000 (Direct Cost: ¥45,000,000)
Fiscal Year 2009: ¥9,000,000 (Direct Cost: ¥9,000,000)
Fiscal Year 2008: ¥9,000,000 (Direct Cost: ¥9,000,000)
Fiscal Year 2007: ¥9,000,000 (Direct Cost: ¥9,000,000)
Fiscal Year 2006: ¥9,000,000 (Direct Cost: ¥9,000,000)
Fiscal Year 2005: ¥9,000,000 (Direct Cost: ¥9,000,000)
|
|---|
| Research Abstract |
Specific blockade of the ERK pathway by MEK inhibitors alone induces mostly cytostatic rather than pro-apoptotic effects, resulting in a limited therapeutic efficacy of MEK inhibitors. However, MEK inhibitors specifically enhance the induction of apoptosis by microtubule-destabilizing agents and HDAC inhibitors in various tumor cells with aberrant activation of the ERK pathway. Our results clearly indicate that administration of both a MEK inhibitor and a microtubule-destabilizing agent/HDAC inhibitor represents a promising chemotherapeutic strategy with improved safety for cancer patients.
|
